Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of “Moderate Buy” from Brokerages

Omeros Corporation (NASDAQ:OMER) has been assigned a consensus rating of “Moderate Buy” from the five ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $40.3333.

A number of equities analysts have recently weighed in on the company. D. Boral Capital reiterated a “buy” rating and issued a $36.00 target price on shares of Omeros in a report on Tuesday, January 27th. Wall Street Zen downgraded shares of Omeros from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. HC Wainwright increased their target price on shares of Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a research note on Thursday, January 22nd.

Insider Transactions at Omeros

In other Omeros news, CAO David J. Borges sold 30,000 shares of the business’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total value of $369,300.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 12.90% of the company’s stock.

Institutional Investors Weigh In On Omeros

Hedge funds and other institutional investors have recently made changes to their positions in the company. State of Wyoming bought a new stake in shares of Omeros in the 4th quarter valued at approximately $25,000. B. Riley Wealth Advisors Inc. acquired a new stake in Omeros in the second quarter valued at approximately $32,000. Caitong International Asset Management Co. Ltd bought a new stake in Omeros in the fourth quarter worth approximately $33,000. Harbour Investments Inc. increased its stake in shares of Omeros by 46.1% during the 2nd quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 4,251 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in shares of Omeros by 829.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 11,971 shares during the last quarter. 48.79% of the stock is owned by hedge funds and other institutional investors.

Omeros Trading Up 4.3%

Shares of OMER stock opened at $12.05 on Friday. Omeros has a 1-year low of $2.95 and a 1-year high of $17.65. The company has a market capitalization of $854.35 million, a price-to-earnings ratio of -5.97 and a beta of 2.44. The stock’s fifty day simple moving average is $12.63 and its 200-day simple moving average is $8.64.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.